Part A: OSE-279 100mg + Part A: OSE-279 300mg + Part A: OSE-279 600mg + Part B: OSE-279 600 mg and OSE2101 + Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive + Part C: OSE-279 600 mg - HLA-A2 positif + Part C: OSE-279 600 mg - HLA-A2 negative
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Advanced Tumor
Conditions
Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer)
Trial Timeline
Dec 20, 2022 → Dec 1, 2029
NCT ID
NCT05751798About Part A: OSE-279 100mg + Part A: OSE-279 300mg + Part A: OSE-279 600mg + Part B: OSE-279 600 mg and OSE2101 + Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive + Part C: OSE-279 600 mg - HLA-A2 positif + Part C: OSE-279 600 mg - HLA-A2 negative
Part A: OSE-279 100mg + Part A: OSE-279 300mg + Part A: OSE-279 600mg + Part B: OSE-279 600 mg and OSE2101 + Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive + Part C: OSE-279 600 mg - HLA-A2 positif + Part C: OSE-279 600 mg - HLA-A2 negative is a phase 1/2 stage product being developed by OSE Immunotherapeutics for Solid Advanced Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05751798. Target conditions include Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer).
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05751798 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Solid Advanced Tumor